GLG News by Rheumatoid Arthritis Specialists (US)

This should not deter the practicing physician to prescribe these agents osteoporosis will reach epidemic proportions and if we can reduce fractures by 50% the savings within the healthcare system will be enormous that's not to say that individuals albeit rare may have a propensity to develop fractures...

Rituxan is no better than placebo in SLE in this study.  Another med bites the dust when tested for SLE.  Further details of this study need to be reviewed.

Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...

A delay in instituting aggressive antirheumatic medications such as the biologic response modifiers has long term implications in irreversible joint damage. Cost considerations (particularly with the looming potential of "universal healthcare" under a new administrations promises) with exponentially...

Lilly needs new treatments and strategies  to maintain position as industry leader.

 In a recent hip fracture intervention trial released on the New England Journal of Medicine website by Lyles, et al on Sept 17,2007 (not scheduled to be released in print until Nov 1 2007) Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture   A placebo controlled study...

European results in a limited number of patients on Exubera for 2-8 years Effectiveness and safety in about a 1/3 of study participants after 8 years

-diabetes and diabetic retinopathy is on the rise due to an increasing epidemic of obesity -diabetic retinopathy is the leading cause of blindness in the United States

-Brain cancer-or more specifically- glioblastomas- are uniformly fatal and treatment -radiation and chemo--is really not effective. -Many younger people are affected by this disease and a cure that is patient specific would be terrific. - This is not the first time that someone has tried to do this...

Pharmacokinetic studies of Adlea showed that when it is locally administered to the site of pain, there appears to be limited systemic exposure. Its short duration of systemic exposure (hours) relative to the long duration of analgesia (12 weeks) resulting from a single treatment course of Adlea is...